The Greenville, South Carolina CCOP has long-term objectives that include: 1) Unifying and funding NCI-supported cancer control and cancer trials in Greenville County, South Carolina, and the surrounding area; 2) Supporting growth and expansion of oncology clinical research in the Greenville area; 3) Expanding the involvement of primary care providers and other specialists in cancer prevention and cancer control in trials; trials; 4) Transferring the latest research finding to residents of the service area; 5) increasing the availability of NCI-supported clinical trials to the substantial minority and undeserved populations in the area. First: the Greenville, South Carolina CCOP will pull together two CCOP's and the beast Cancer Prevention Trial already in place by establishing a funded data management office at the Cancer Treatment Center at Greenville Memorial Hospital, a component of the Greenville Hospital system (GHS). If these two CCOPs have been a CCOP in calendar year 1993, the therapy accruals from SWOG, NSABP, and RTOG would have been 97 patients and 98 credits; and the cancer control accruals would have been 43 patients and 43.1 credits. If the GOG were a research base, an additional 6 patients would be added to therapy accruals (Tables 8A and 8C). Second: the CCOP will serve the increased need for data management in a community where surgical, gynecological, radiation, and medical oncologist are already committed to cancer clinical research through the NCI. The number of medical oncologist have increased from five to seven, and the number of gynecologic oncologist has increased from zero to two in 1994. At the same time, the indications for participation in clinical trials and the numbers of clinical trials are increasing. In particular, increased lung cancer (SWOG 9221) and ENT (SWOG 9043) chemoprevention studies are anticipated. Third and fourth: cancer control programs through the COOP will extend beyond the oncologist and will enlist the anticipation of primary care and other physicians. For example, chemoprevention and dietary trials for colorectal (SWOG 9041), gynecologic, and aerodigestive cancers will reach out to physicians who have been only peripherally involved in cancer research in the past. The availability of these trials to the community will be a mechanism used by the COOP to promote overall cancer control awareness and education in the community. The addition of Wake Forest as a research base will allow the use of previously unavailable cancer control studies related to breast cancer and colon cancer. Fifth: Virtually all of the oncology care in Greenville County is provided at the component and affiliate site of the CCOP, allowing expanded access to NCI clinical trials for the minority and undeserved rural populations who are already seen at these sites.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA067663-01
Application #
2111410
Study Section
Special Emphasis Panel (SRC (16))
Project Start
1995-09-25
Project End
1998-05-31
Budget Start
1995-09-25
Budget End
1996-05-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Oncology & Hematology Associates of SC
Department
Type
DUNS #
City
Greenville
State
SC
Country
United States
Zip Code
29605
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Advani, Anjali S; McDonough, Shannon; Coutre, Steven et al. (2014) SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165:504-9
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 95 publications